E
Sage Therapeutics, Inc.
SAGE
$7.86
-$0.16-2.00%
E
Sell
8/26/2024Downgrade
Sage Therapeutics, Inc. (SAGE) was downgraded to E+ from D- on 8/26/2024 due to a large decline in the solvency index, total return index and volatility index. The quick ratio declined from 11.77 to 9.51.
Sage Therapeutics, Inc. (SAGE) was downgraded to E+ from D- on 8/26/2024 due to a large decline in the solvency index, total return index and volatility index. The quick ratio declined from 11.77 to 9.51.
D
Sell
6/3/2024Upgraded
Sage Therapeutics, Inc. (SAGE) was upgraded to D- from E+ on 6/3/2024 due to an increase in the volatility index and valuation index.
Sage Therapeutics, Inc. (SAGE) was upgraded to D- from E+ on 6/3/2024 due to an increase in the volatility index and valuation index.
E
Sell
5/17/2024Downgrade
Sage Therapeutics, Inc. (SAGE) was downgraded to E+ from D- on 5/17/2024 due to a decline in the volatility index, total return index and growth index.
Sage Therapeutics, Inc. (SAGE) was downgraded to E+ from D- on 5/17/2024 due to a decline in the volatility index, total return index and growth index.
D
Sell
4/26/2024Upgraded
Sage Therapeutics, Inc. (SAGE) was upgraded to D- from E+ on 4/26/2024 due to an increase in the solvency index and volatility index. Debt to equity declined from 0.01 to 0, and the quick ratio increased from 10.12 to 11.77.
Sage Therapeutics, Inc. (SAGE) was upgraded to D- from E+ on 4/26/2024 due to an increase in the solvency index and volatility index. Debt to equity declined from 0.01 to 0, and the quick ratio increased from 10.12 to 11.77.
E
Sell
4/11/2024Downgrade
Sage Therapeutics, Inc. (SAGE) was downgraded to E+ from D- on 4/11/2024 due to a decline in the volatility index and total return index.
Sage Therapeutics, Inc. (SAGE) was downgraded to E+ from D- on 4/11/2024 due to a decline in the volatility index and total return index.
D
Sell
3/25/2024Upgraded
Sage Therapeutics, Inc. (SAGE) was upgraded to D- from E+ on 3/25/2024 due to an increase in the volatility index.
Sage Therapeutics, Inc. (SAGE) was upgraded to D- from E+ on 3/25/2024 due to an increase in the volatility index.
E
Sell
3/6/2024Downgrade
Sage Therapeutics, Inc. (SAGE) was downgraded to E+ from D- on 3/6/2024 due to a decline in the volatility index.
Sage Therapeutics, Inc. (SAGE) was downgraded to E+ from D- on 3/6/2024 due to a decline in the volatility index.
D
Sell
2/16/2024Upgraded
Sage Therapeutics, Inc. (SAGE) was upgraded to D- from E+ on 2/16/2024 due to a noticeable increase in the solvency index, growth index and volatility index. Total revenue increased 2,770.84% from $2.72M to $77.97M, earnings per share increased from -$3.3654 to -$0.5452, and EBIT increased 76.28% from -$178.25M to -$42.29M.
Sage Therapeutics, Inc. (SAGE) was upgraded to D- from E+ on 2/16/2024 due to a noticeable increase in the solvency index, growth index and volatility index. Total revenue increased 2,770.84% from $2.72M to $77.97M, earnings per share increased from -$3.3654 to -$0.5452, and EBIT increased 76.28% from -$178.25M to -$42.29M.
E
Sell
2/7/2024Downgrade
Sage Therapeutics, Inc. (SAGE) was downgraded to E+ from D- on 2/7/2024 due to a decline in the volatility index, growth index and valuation index.
Sage Therapeutics, Inc. (SAGE) was downgraded to E+ from D- on 2/7/2024 due to a decline in the volatility index, growth index and valuation index.
D
Sell
11/14/2023Upgraded
Sage Therapeutics, Inc. (SAGE) was upgraded to D- from E+ on 11/14/2023 due to an increase in the growth index and valuation index. Total revenue increased 9.78% from $2.47M to $2.72M.
Sage Therapeutics, Inc. (SAGE) was upgraded to D- from E+ on 11/14/2023 due to an increase in the growth index and valuation index. Total revenue increased 9.78% from $2.47M to $2.72M.
E
Sell
11/7/2023Downgrade
Sage Therapeutics, Inc. (SAGE) was downgraded to E+ from D- on 11/7/2023 due to a large decline in the total return index, volatility index and growth index. Total revenue declined 24.89% from $3.29M to $2.47M, EBIT declined 9.64% from -$155.47M to -$170.46M, and earnings per share declined from -$2.4605 to -$2.6824.
Sage Therapeutics, Inc. (SAGE) was downgraded to E+ from D- on 11/7/2023 due to a large decline in the total return index, volatility index and growth index. Total revenue declined 24.89% from $3.29M to $2.47M, EBIT declined 9.64% from -$155.47M to -$170.46M, and earnings per share declined from -$2.4605 to -$2.6824.
D
Sell
3/14/2023Downgrade
Sage Therapeutics, Inc. (SAGE) was downgraded to D- from D on 3/14/2023 due to a decline in the efficiency index and solvency index. Total capital declined 9.27% from $1.39B to $1.26B, the quick ratio declined from 14.17 to 12.97, and net income declined 7.15% from -$137.32M to -$147.15M.
Sage Therapeutics, Inc. (SAGE) was downgraded to D- from D on 3/14/2023 due to a decline in the efficiency index and solvency index. Total capital declined 9.27% from $1.39B to $1.26B, the quick ratio declined from 14.17 to 12.97, and net income declined 7.15% from -$137.32M to -$147.15M.
D
Sell
11/9/2022Upgraded
Sage Therapeutics, Inc. (SAGE) was upgraded to D from D- on 11/9/2022 due to an increase in the growth index, volatility index and total return index. Total revenue increased 15.86% from $1.5M to $1.74M.
Sage Therapeutics, Inc. (SAGE) was upgraded to D from D- on 11/9/2022 due to an increase in the growth index, volatility index and total return index. Total revenue increased 15.86% from $1.5M to $1.74M.
D
Sell
2/28/2022Downgrade
Sage Therapeutics, Inc. (SAGE) was downgraded to D- from D on 2/28/2022 due to a significant decline in the valuation index, growth index and efficiency index. Operating cash flow declined 41.66% from -$68.83M to -$97.5M, and total capital declined 5.83% from $1.86B to $1.75B.
Sage Therapeutics, Inc. (SAGE) was downgraded to D- from D on 2/28/2022 due to a significant decline in the valuation index, growth index and efficiency index. Operating cash flow declined 41.66% from -$68.83M to -$97.5M, and total capital declined 5.83% from $1.86B to $1.75B.
D
Sell
9/22/2021Downgrade
Sage Therapeutics, Inc. (SAGE) was downgraded to D from D+ on 9/22/2021 due to a large decline in the total return index and valuation index.
Sage Therapeutics, Inc. (SAGE) was downgraded to D from D+ on 9/22/2021 due to a large decline in the total return index and valuation index.
D
Sell
8/4/2021Upgraded
Sage Therapeutics, Inc. (SAGE) was upgraded to D+ from D on 8/4/2021 due to a significant increase in the growth index and valuation index. Operating cash flow increased 5.79% from -$109.09M to -$102.77M, and total revenue increased 3.79% from $1.58M to $1.64M.
Sage Therapeutics, Inc. (SAGE) was upgraded to D+ from D on 8/4/2021 due to a significant increase in the growth index and valuation index. Operating cash flow increased 5.79% from -$109.09M to -$102.77M, and total revenue increased 3.79% from $1.58M to $1.64M.
D
Sell
5/13/2021Downgrade
Sage Therapeutics, Inc. (SAGE) was downgraded to D from D+ on 5/13/2021 due to a decline in the volatility index.
Sage Therapeutics, Inc. (SAGE) was downgraded to D from D+ on 5/13/2021 due to a decline in the volatility index.
D
Sell
5/6/2021Downgrade
Sage Therapeutics, Inc. (SAGE) was downgraded to D+ from C- on 5/6/2021 due to a significant decline in the growth index and solvency index. Operating cash flow declined 110.79% from $1.01B to -$109.09M, EBIT declined 109.91% from $973.85M to -$96.51M, and earnings per share declined from $18.1845 to -$1.6405.
Sage Therapeutics, Inc. (SAGE) was downgraded to D+ from C- on 5/6/2021 due to a significant decline in the growth index and solvency index. Operating cash flow declined 110.79% from $1.01B to -$109.09M, EBIT declined 109.91% from $973.85M to -$96.51M, and earnings per share declined from $18.1845 to -$1.6405.
C
Hold
3/2/2021Upgraded
Sage Therapeutics, Inc. (SAGE) was upgraded to C- from D+ on 3/2/2021 due to an increase in the total return index.
Sage Therapeutics, Inc. (SAGE) was upgraded to C- from D+ on 3/2/2021 due to an increase in the total return index.
D
Sell
2/26/2021Upgraded
Sage Therapeutics, Inc. (SAGE) was upgraded to D+ from D on 2/26/2021 due to a significant increase in the valuation index, growth index and efficiency index. Total revenue increased 67,574.56% from $1.64M to $1.11B, operating cash flow increased 1,210.76% from -$91.02M to $1.01B, and net income increased 1,022.02% from -$105.74M to $974.9M.
Sage Therapeutics, Inc. (SAGE) was upgraded to D+ from D on 2/26/2021 due to a significant increase in the valuation index, growth index and efficiency index. Total revenue increased 67,574.56% from $1.64M to $1.11B, operating cash flow increased 1,210.76% from -$91.02M to $1.01B, and net income increased 1,022.02% from -$105.74M to $974.9M.
D
Sell
5/8/2020Upgraded
Sage Therapeutics, Inc. (SAGE) was upgraded to D from D- on 5/8/2020 due to a noticeable increase in the growth index and valuation index. Earnings per share increased from -$3.2537 to -$2.4416, EBIT increased 24.63% from -$174.64M to -$131.62M, and total revenue increased 16.63% from $1.96M to $2.29M.
Sage Therapeutics, Inc. (SAGE) was upgraded to D from D- on 5/8/2020 due to a noticeable increase in the growth index and valuation index. Earnings per share increased from -$3.2537 to -$2.4416, EBIT increased 24.63% from -$174.64M to -$131.62M, and total revenue increased 16.63% from $1.96M to $2.29M.
D
Sell
8/8/2019Downgrade
Sage Therapeutics, Inc. (SAGE) was downgraded to D- from D on 8/8/2019 due to a decline in the efficiency index and total return index. Total capital declined 8.64% from $1.36B to $1.24B, and net income declined 2.95% from -$163.41M to -$168.22M.
Sage Therapeutics, Inc. (SAGE) was downgraded to D- from D on 8/8/2019 due to a decline in the efficiency index and total return index. Total capital declined 8.64% from $1.36B to $1.24B, and net income declined 2.95% from -$163.41M to -$168.22M.
D
Sell
5/7/2018Upgraded
Sage Therapeutics, Inc. (SAGE) was upgraded to D from D- on 5/7/2018 due to an increase in the efficiency index, solvency index and volatility index. The quick ratio increased from 9.99 to 28.61, and total capital increased 122.78% from $475.48M to $1.06B.
Sage Therapeutics, Inc. (SAGE) was upgraded to D from D- on 5/7/2018 due to an increase in the efficiency index, solvency index and volatility index. The quick ratio increased from 9.99 to 28.61, and total capital increased 122.78% from $475.48M to $1.06B.
D
Sell
5/12/2017Downgrade
Sage Therapeutics, Inc. (SAGE) was downgraded to D- from D on 5/12/2017 due to a decline in the growth index, solvency index and valuation index. Operating cash flow declined 63.46% from -$33.78M to -$55.21M, the quick ratio declined from 11.3 to 10.74, and EBIT declined 1.95% from -$56.38M to -$57.48M.
Sage Therapeutics, Inc. (SAGE) was downgraded to D- from D on 5/12/2017 due to a decline in the growth index, solvency index and valuation index. Operating cash flow declined 63.46% from -$33.78M to -$55.21M, the quick ratio declined from 11.3 to 10.74, and EBIT declined 1.95% from -$56.38M to -$57.48M.
D
Sell
5/9/2016Upgraded
Sage Therapeutics, Inc. (SAGE) was upgraded to D from D- on 5/9/2016 due to an increase in the efficiency index, valuation index and solvency index. Total capital increased 65.52% from $173.7M to $287.5M, and the quick ratio increased from 12.2 to 18.77.
Sage Therapeutics, Inc. (SAGE) was upgraded to D from D- on 5/9/2016 due to an increase in the efficiency index, valuation index and solvency index. Total capital increased 65.52% from $173.7M to $287.5M, and the quick ratio increased from 12.2 to 18.77.
D
Sell
1/15/2016Downgrade
Sage Therapeutics, Inc. (SAGE) was downgraded to D- from D on 1/15/2016 due to a large decline in the volatility index, solvency index and growth index. Earnings per share declined from -$0.8983 to -$0.8364, EBIT declined 3.9% from -$25.06M to -$24.08M, and the quick ratio declined from 20.38 to 19.91.
Sage Therapeutics, Inc. (SAGE) was downgraded to D- from D on 1/15/2016 due to a large decline in the volatility index, solvency index and growth index. Earnings per share declined from -$0.8983 to -$0.8364, EBIT declined 3.9% from -$25.06M to -$24.08M, and the quick ratio declined from 20.38 to 19.91.
D
Sell
2/11/2015Upgraded
Sage Therapeutics, Inc. (SAGE) was upgraded to D from E+ on 2/11/2015 due to an increase in the volatility index.
Sage Therapeutics, Inc. (SAGE) was upgraded to D from E+ on 2/11/2015 due to an increase in the volatility index.
E
Sell
2/6/2015Downgrade
Sage Therapeutics, Inc. (SAGE) was downgraded to E+ from D on 2/6/2015 due to a decline in the total return index.
Sage Therapeutics, Inc. (SAGE) was downgraded to E+ from D on 2/6/2015 due to a decline in the total return index.
D
Sell
2/5/2015Upgraded
Sage Therapeutics, Inc. (SAGE) was upgraded to D from E+ on 02/05/2015.
Sage Therapeutics, Inc. (SAGE) was upgraded to D from E+ on 02/05/2015.
E
Sell
2/4/2015Downgrade
Sage Therapeutics, Inc. (SAGE) was downgraded to E+ from D on 2/4/2015 due to a decline in the total return index.
Sage Therapeutics, Inc. (SAGE) was downgraded to E+ from D on 2/4/2015 due to a decline in the total return index.
D
Sell
1/26/2015Upgraded
Sage Therapeutics, Inc. (SAGE) was upgraded to D from E+ on 1/26/2015 due to an increase in the volatility index.
Sage Therapeutics, Inc. (SAGE) was upgraded to D from E+ on 1/26/2015 due to an increase in the volatility index.
E
Sell
1/15/2015Downgrade
Sage Therapeutics, Inc. (SAGE) was downgraded to E+ from D on 01/15/2015.
Sage Therapeutics, Inc. (SAGE) was downgraded to E+ from D on 01/15/2015.
D
Sell
1/7/2015Upgraded
Sage Therapeutics, Inc. (SAGE) was upgraded to D from E+ on 1/7/2015 due to an increase in the total return index and volatility index.
Sage Therapeutics, Inc. (SAGE) was upgraded to D from E+ on 1/7/2015 due to an increase in the total return index and volatility index.
E
Sell
1/6/2015Downgrade
Sage Therapeutics, Inc. (SAGE) was downgraded to E+ from D on 1/6/2015 due to a decline in the total return index.
Sage Therapeutics, Inc. (SAGE) was downgraded to E+ from D on 1/6/2015 due to a decline in the total return index.
D
Sell
1/5/2015Upgraded
Sage Therapeutics, Inc. (SAGE) was upgraded to D from E on 1/5/2015 due to an increase in the volatility index.
Sage Therapeutics, Inc. (SAGE) was upgraded to D from E on 1/5/2015 due to an increase in the volatility index.
E
Sell
12/24/2014Downgrade
Sage Therapeutics, Inc. (SAGE) was downgraded to E from D on 12/24/2014.
Sage Therapeutics, Inc. (SAGE) was downgraded to E from D on 12/24/2014.
D
Sell
12/17/2014Upgraded
Sage Therapeutics, Inc. (SAGE) was upgraded to D from E on 12/17/2014 due to an increase in the volatility index and total return index.
Sage Therapeutics, Inc. (SAGE) was upgraded to D from E on 12/17/2014 due to an increase in the volatility index and total return index.
E
Sell
12/11/2014Downgrade
Sage Therapeutics, Inc. (SAGE) was downgraded to E from D on 12/11/2014.
Sage Therapeutics, Inc. (SAGE) was downgraded to E from D on 12/11/2014.
D
Sell
12/2/2014Upgraded
Sage Therapeutics, Inc. (SAGE) was upgraded to D from E on 12/2/2014 due to an increase in the volatility index and total return index.
Sage Therapeutics, Inc. (SAGE) was upgraded to D from E on 12/2/2014 due to an increase in the volatility index and total return index.
E
Sell
12/1/2014Downgrade
Sage Therapeutics, Inc. (SAGE) was downgraded to E from D on 12/1/2014 due to a decline in the volatility index.
Sage Therapeutics, Inc. (SAGE) was downgraded to E from D on 12/1/2014 due to a decline in the volatility index.
D
Sell
11/24/2014Upgraded
Sage Therapeutics, Inc. (SAGE) was upgraded to D from E on 11/24/2014 due to a noticeable increase in the solvency index, growth index and volatility index. The quick ratio increased from 12.5 to 27.29, EBIT increased 53.04% from -$6.19M to -$9.47M, and operating cash flow increased 41.97% from -$5.27M to -$7.49M.
Sage Therapeutics, Inc. (SAGE) was upgraded to D from E on 11/24/2014 due to a noticeable increase in the solvency index, growth index and volatility index. The quick ratio increased from 12.5 to 27.29, EBIT increased 53.04% from -$6.19M to -$9.47M, and operating cash flow increased 41.97% from -$5.27M to -$7.49M.
E
Sell
11/7/2014Downgrade
Sage Therapeutics, Inc. (SAGE) was downgraded to E from D on 11/07/2014.
Sage Therapeutics, Inc. (SAGE) was downgraded to E from D on 11/07/2014.
D
Sell
11/6/2014Upgraded
Sage Therapeutics, Inc. (SAGE) was upgraded to D from E on 11/6/2014 due to an increase in the total return index and volatility index.
Sage Therapeutics, Inc. (SAGE) was upgraded to D from E on 11/6/2014 due to an increase in the total return index and volatility index.
E
Sell
11/5/2014Downgrade
Sage Therapeutics, Inc. (SAGE) was downgraded to E from D on 11/5/2014 due to a decline in the valuation index.
Sage Therapeutics, Inc. (SAGE) was downgraded to E from D on 11/5/2014 due to a decline in the valuation index.
D
Sell
11/4/2014Upgraded
Sage Therapeutics, Inc. (SAGE) was upgraded to D from E on 11/4/2014 due to an increase in the total return index and volatility index.
Sage Therapeutics, Inc. (SAGE) was upgraded to D from E on 11/4/2014 due to an increase in the total return index and volatility index.
E
Sell
11/3/2014Downgrade
Sage Therapeutics, Inc. (SAGE) was downgraded to E from D on 11/3/2014 due to a decline in the volatility index.
Sage Therapeutics, Inc. (SAGE) was downgraded to E from D on 11/3/2014 due to a decline in the volatility index.
D
Sell
10/30/2014Upgraded
Sage Therapeutics, Inc. (SAGE) was upgraded to D from E on 10/30/2014 due to an increase in the total return index and volatility index.
Sage Therapeutics, Inc. (SAGE) was upgraded to D from E on 10/30/2014 due to an increase in the total return index and volatility index.
E
Sell
10/29/2014Downgrade
Sage Therapeutics, Inc. (SAGE) was downgraded to E from D on 10/29/2014 due to a decline in the volatility index.
Sage Therapeutics, Inc. (SAGE) was downgraded to E from D on 10/29/2014 due to a decline in the volatility index.
D
Sell
10/28/2014Upgraded
Sage Therapeutics, Inc. (SAGE) was upgraded to D from E on 10/28/2014 due to a major increase in the total return index and volatility index.
Sage Therapeutics, Inc. (SAGE) was upgraded to D from E on 10/28/2014 due to a major increase in the total return index and volatility index.
E
Sell
10/13/2014None
Sage Therapeutics, Inc. (SAGE) was downgraded to E from U on 10/13/2014.
Sage Therapeutics, Inc. (SAGE) was downgraded to E from U on 10/13/2014.
NASDAQ
03/18/2025 4:00PM Eastern
Quotes delayed
